Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 4

Long-term therapy in COPD: any evidence of adverse effect on bone?

Authors Arnulf Langhammer, Siri Forsmo, Unni Syversen

Published Date September 2009 Volume 2009:4 Pages 365—380

DOI http://dx.doi.org/10.2147/COPD.S4797

Published 30 September 2009

Arnulf Langhammer1, Siri Forsmo2, Unni Syversen3,4

1HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology (NTNU), Verdal, Norway; 2Department of Public Health and General Practice, NTNU, Trondheim, Norway; 3Department of Cancer Research and Molecular Medicine, NTNU, Trondheim, Norway; 4Department of Endocrinology, St. Olav’s University Hospital, Trondheim, Norway

Abstract: Patients with COPD have high risk for osteoporosis and fractures. Hip and vertebral fractures might impair mobility, and vertebral fractures further reduce lung function. This review discusses the evidence of bone loss due to medical treatment opposed to disease severity and risk factors for COPD, and therapeutic options for the prevention and treatment of osteoporosis in these patients. A review of the English-language literature was conducted using the MEDLINE database until June 2009. Currently used bronchodilators probably lack adverse effect on bone. Oral corticosteroids (OCS) increase bone resorption and decrease bone formation in a dose response relationship, but the fracture risk is increased more than reflected by bone densitometry. Inhaled corticosteroids (ICS) have been associated with both increased bone loss and fracture risk. This might be a result of confounding by disease severity, but high doses of ICS have similar effects as equipotent doses of OCS. The life-style factors should be modified, use of regular OCS avoided and use of ICS restricted to those with evidenced effect and probably kept at moderate doses. The health care should actively reveal risk factors, include bone densitometry in fracture risk evaluation, and give adequate prevention and treatment for osteoporosis.

Keywords: COPD, corticosteroids, bronchodilators, bone mineral density, osteoporosis, fractures

General overview

Licence for Fig 2 is uploaded

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Mécano-Stimulation™ of the skin improves sagging score and induces beneficial functional modification of the fibroblasts: clinical, biological, and histological evaluations

Humbert P, Fanian F, Lihoreau T, Jeudy A, Elkhyat A, Robin S, Courderot-Masuyer C, Tauzin H, Lafforgue C, Haftek M

Clinical Interventions in Aging 2015, 10:387-403

Published Date: 2 February 2015

Associated bone mineral density and obstructive sleep apnea in chronic obstructive pulmonary disease

Wang TY, Lo YL, Chou PC, Chung FT, Lin SM, Lin TY, Lin HC, Wang CH, Yu CT, Kuo HP

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:231-237

Published Date: 29 January 2015

Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups

Assaad-Khalil SH, Najem R, Sison J, Kitchlew AR, Cho BL, Ueng KC, DiTommaso S, Shete A

Vascular Health and Risk Management 2015, 11:71-78

Published Date: 21 January 2015

Knowledge about COPD among users of primary health care services

Queiroz MC, Moreira MA, Jardim JR, Barbosa MA, Minamisava R, Gondim HD, Velasco FC, Penhavel MV

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1-6

Published Date: 17 December 2014

Proliferation and stemness preservation of human adipose-derived stem cells by surface-modified in situ TiO2 nanofibrous surfaces

Tan AW, Tay L, Chua KH, Ahmad R, Ali Akbar S, Pingguan-Murphy B

International Journal of Nanomedicine 2014, 9:5389-5401

Published Date: 21 November 2014

Glistenings in hydrophobic acrylic intraocular lenses do affect visual function

Beiko GHH, Grzybowski A

Clinical Ophthalmology 2013, 7:2271-2274

Published Date: 27 November 2013

Metabolic pathway and distribution of superparamagnetic iron oxide nanoparticles: in vivo study

Schlachter EK, Widmer HR, Bregy A, Lönnfors-Weitzel T, Vajtai I, Corazza N, Bernau VJP, Weitzel T, Mordasini P, Slotboom J, Herrmann G, Bogni S, Hofmann H, Frenz M, Reinert M

International Journal of Nanomedicine 2011, 6:1793-1800

Published Date: 26 August 2011

New therapeutic options in the management of COPD – focus on roflumilast

Sabina Antonela Antoniu

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:147-155

Published Date: 17 February 2011